Plasminogen activator inhibitor 1: Mechanisms of its synergistic regulation by growth factors

Song, Xiaoling

doi:10.2172/1048513

Cited by 1 publication

(2 citation statements)

References 317 publications

(236 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alteplase has been studied extensively and proven useful in the fields of neurology and cardiovascular disease as an emergency intravenous therapy to induce fibrinolysis in cases with occlusion of blood vessels. Prior study of alteplase in ophthalmology revealed it decreased PAI-1 levels significantly in an in vitro experimental study using cultures of HLECs (Song, 2010;Nishi, 2012;Ghatak et al, 2018;Wulandari et al, 2019).…”

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Attenuation of Transforming Growth Factor-? Expression by Alteplase in Anterior Lens Capsule Fibrosis Model with Fibrin Reaction In Vitro

Sitorus¹,

Mustika²,

Notobroto³

et al. 2021

IJRP

View full text Add to dashboard Cite

Background: Underlying pathophysiology of posterior capsule opacification, a frequent visual disturbance postop complication of cataract surgery, is multifactorial. Several cytokines and growth factors, such as Transforming Growth Factor-β (TGF-β), Fibroblast Growth Factor 2 (FGF-2), and Hepatocyte Growth Factor (HGF), have been found to play roles in the formation of PCO. Multiple advancements have been made including researches in therapeutic agents. Alteplase, a fibrinolytic agent, has been studied to decrease fibrin formation, which is a mechanism causing PCO. This study aimed to investigate the effect of alteplase on TGF-β expression in an anterior lens capsule fibrosis model resembling PCO. Methods: An experimental study was performed using cultured anterior lens capsule tissue taken during cataract surgery. Primary cell isolation culture and lens epithelial lens characterization were conducted. Following identification of lens epithelial cell and 90% confluency rate on cell culture, lens epithelial cells were divided into four groups and then scratched to induce inflammatory reaction resembling PCO process after cataract surgery. Doses of 25 mcg/ml, 50 mcg/ml, and 100 mcg/ml were then applied to each group of cell cultures with the other group serving as negative control. Using a fluorescein microscope, measurements to asses the influence of alteplase were taken 7 days after scratching by analyzing the intensity of fluoresce using FITC antibody of TGF-β. Results: The attenuation effect of alteplase to TGF-β expression was observed in all treatment groups; 25 µg/ml (15.5716x106 ±2.56558x10 6 ), 50 µg/ml (12.7364x106 ±1.67067x10 6 ), and 100 µg/ml group (7.8422x106 ±2.24941x106). The Tukey HSD posthoc tests found significant decrease between control group and each treatment group (p=0.019, p=0.000, and p=0.000; respectively). Conclusion: Alteplase within measure dose range holds potential effect in inhibiting fibrosis formation in PCO through attenuation of TGF-β

show abstract

Section: Discussionmentioning

confidence: 95%

“…Meng et al (2013) mTOR is activated by TGF-β -induced EMT. TGF-β functions through 2 pathways, Smad dependent which has Smad 1 to 5 components and Smad independent pathways which consists of Rho-GTPase, phosphatidilinositol-3-kinase and MAPK (Wormstone et al, 2004;Dotan et al, 2013;Chen et al, 2014;Song, 2010).…”

Section: Discussionmentioning

confidence: 99%